Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Core Viewpoint - Enliven Therapeutics, Inc. announced updated Phase 1a data for its small molecule kinase inhibitor ELVN-001, which will be presented at the ESH-iCMLf 26th Annual John Goldman Conference in Prague from September 27-29, 2024 [1]. Group 1: Product Information - ELVN-001 is a potent and highly selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion, which is the oncogenic driver for chronic myeloid leukemia (CML) patients [2]. Group 2: Presentation Details - The oral presentation will cover the preliminary safety and efficacy of ELVN-001, presented by Dr. Fabian Lang from Goethe University Hospital [3]. - The session is scheduled for September 28, 2024, from 3:00 to 4:20 p.m. CEST, with the presentation taking place from 3:35 to 3:50 p.m. CEST [3]. Group 3: Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors aimed at improving the lives of cancer patients through precision oncology [4]. - The company aims to address unmet needs in cancer treatment by designing potentially first-in-class or best-in-class therapies based on insights into clinically validated biological targets [4].